drugset / Trial / NCT00619528
HLA-Identical Sibling Renal Transplant Tolerance
Completed
88 enrolled
Northwestern University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to attempt to eliminate the necessity of immunosuppressive therapy for HLA-identical sibling Kidney Transplants, examine cellular chimerism of donor hematopoietic stem cell (DHSC) lineages for pairs to demonstrate immunologic unresponsiveness, and to investigate the safety and efficacy of the treatment regimen including withdrawal of immunosuppression after one year post-transplant for those recipients having received DHSC infusions.
Timeline
- Start
- 2008-01
- Primary completion
- 2022-07
- Completion
- 2023-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alemtuzumab | Monoclonal antibody | — | — |
| Subject | Donor Hematopoietic Stem Cells | Cell therapy | — | — |
| Background | Mycophenolate Mofetil | Small molecule | — | — |
| Background | Sirolimus | Small molecule | — | — |
| Background | Tacrolimus | Small molecule | — | — |